Ad
related to: potency pharmacology of amoxicillin 2 times 1 10 mg 5
Search results
Results From The WOW.Com Content Network
Antimicrobial pharmacodynamics is the relationship between the concentration of an antibiotic and its ability to inhibit vital processes of endo- or ectoparasites and microbial organisms. [1] This branch of pharmacodynamics relates the concentration of an anti-infective agent to its effect, specifically to its antimicrobial effect.
In pharmacology, potency or biological potency [1] is a measure of a drug's biological activity expressed in terms of the dose required to produce a pharmacological effect of given intensity. [2]
So, the maintenance dose of foosporin is 100 milligrams (100 mg) per day—just enough to offset the amount cleared. Suppose a patient just started taking 100 mg of foosporin every day. On the first day, they'd have 100 mg in their system; their body would clear 10 mg, leaving 90 mg.
It is commonly used as a measure of a drug's potency, although the use of EC 50 is preferred over that of 'potency', which has been criticised for its vagueness. [3] EC 50 is a measure of concentration, expressed in molar units (M), where 1 M is equivalent to 1 mol / L .
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
The value obtained is largely dependent on the susceptibility of the microorganism and the antimicrobial potency of the chemical, but other variables can affect results too. [5] The MIC is often expressed in micrograms per milliliter (μg/mL) or milligrams per liter (mg/L).
The area under the effect curve (AUEC) is an integral of the effect of a drug over time, estimated as a previously-established function of concentration. It was proposed to be used instead of AUC in animal-to-human dose translation, as computer simulation shows that it could cope better with half-life and dosing schedule variations than AUC.
Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans.